HC Wainwright Weighs in on Nuvectis Pharma Q1 Earnings

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Nuvectis Pharma in a note issued to investors on Wednesday, February 11th. HC Wainwright analyst J. Pantginis anticipates that the company will earn ($0.29) per share for the quarter. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Nuvectis Pharma’s Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.32) EPS.

Nuvectis Pharma (NASDAQ:NVCT) last issued its earnings results on Wednesday, February 11th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.05).

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $15.33.

Nuvectis Pharma Stock Up 0.5%

Shares of NASDAQ NVCT opened at $8.78 on Thursday. Nuvectis Pharma has a 12 month low of $5.55 and a 12 month high of $11.52. The company has a market cap of $224.86 million, a price-to-earnings ratio of -6.41 and a beta of -0.29. The business has a fifty day simple moving average of $8.10 and a 200-day simple moving average of $6.93.

Institutional Trading of Nuvectis Pharma

A number of hedge funds have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Nuvectis Pharma during the second quarter worth approximately $28,000. JPMorgan Chase & Co. lifted its position in Nuvectis Pharma by 3,398.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock worth $47,000 after buying an additional 6,084 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Nuvectis Pharma during the 2nd quarter valued at $53,000. Avalon Trust Co purchased a new position in shares of Nuvectis Pharma during the 3rd quarter valued at $60,000. Finally, Bank of America Corp DE increased its stake in shares of Nuvectis Pharma by 417.2% in the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock worth $64,000 after acquiring an additional 6,909 shares during the last quarter. 96.77% of the stock is owned by hedge funds and other institutional investors.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.